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We have examined the in vivo effect of hepatitis B virus (HBV) core promoter mutations on the expression of precore mRNA
and pregenomic RNA transcripts in the liver of 24 patients with chronic HBV infection, applying a novel transcript-specific
RT-PCR assay. The double A1762T/G1764A mutation in the basic core promoter was detected in 11 cases. This mutation was
in all cases associated with absence or low levels of precore mRNA transcripts without significantly affecting the levels of
total core promoter-directed transcription in the liver of infected patients. Precore mRNA synthesis was suppressed by the
A1762T/G1764A mutation regardless of the presence of the precore stop codon mutation G1896A, suggesting that in addition
to downregulating an immunomodulatory protein this double basic core promoter mutation may also confer a replication
advantage to the virus. Additional mutations detected in the core promoter may also contribute to the observed changes inINTRODUCTION
In the natural course of chronic hepatitis B virus (HBV)
infection the development and selection of mutations in
the HBV genome may become clinically relevant and
influence the outcome of infection (Gunther et al., 1999;
Hunt et al., 2000). The accumulation of certain mutants
depends not only on the time factor and the resistance
toward immune pressure or antiviral drugs but also on
the replication activity and the rate of elimination of
wild-type viruses. The best characterized and more prev-
alent mutation in HBeAg-negative patients with chronic
HBV infection is a G to A change at nucleotide (nt) 1896
(G1896A), which introduces a novel translational stop
codon leading to premature termination of the precore
protein synthesis, the precursor of HBeAg, thus abolish-
ing its production (Carman et al., 1989). Although a num-
ber of other mutations preventing HBeAg synthesis have
been identified in the coding region of the precore pro-
tein (Sanantonio et al., 1991; Lok et al., 1994; Laras et al.,
1998), the G1896A change predominates, particularly in
non-A HBV genotypes common in Asia and the Mediter-
ranean region. This mutation is present in the majority of
patients with HBeAg-negative chronic hepatitis B (CHB)
with ongoing HBV replication (Hadziyannis, 1995).
Mutations in the HBV core promoter (CP) have also
been found to be common among HBeAg() patients
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All rights rewith chronic HBV infection (Okamoto et al., 1994; Kuro-
saki et al., 1996; Kidd-Ljunggren et al., 1997) and have
been associated with a more aggressive course of liver
disease (Sato et al., 1995; Baumert et al., 1996; Gunther
et al., 1996; Sterneck et al., 1996; MacMillan et al., 1996;
Pult et al., 1997). The HBV core promoter plays a central
role in the replication and the life cycle of the virus by
directing the synthesis of two types of 3.5-kb viral tran-
scripts that differ at their 5-initiation sites (Will et al.,
1987; Yaginuma et al., 1987). The shorter pregenomic (pg)
RNA, initiated at nt 1815  5, serves as the mRNA for the
core and polymerase genes and following encapsidation
as the template for reverse transcription to generate viral
DNA. The slightly larger precore (preC) mRNA is initiated
15–35 bp upstream of the pgRNA start sites and contains
an additional upstream in-frame translational initiation
signal. Translation from this start codon leads to the
synthesis of the precore protein, the HBeAg precursor,
which is secreted in the serum after posttranslational
modification (Takahashi et al., 1991).
The HBV core promoter spans a region of approxi-
mately 230 bp which consists of the basic core promoter
(BCP) (nts 1742–1849), the sufficient and necessary se-
quence for the accurate initiation and transcription of
both preC mRNA and pg RNA (Yuh et al., 1992; Chen et
al., 1995; Yu and Mertz, 1996), and the upstream regula-
tory region (URR) (nts 1613–1742), which contains both
negative- and positive-regulatory sequences. The nega-
tive regulatory element (NRE) (nts 1613–1636) inhibits in
cis core promoter activity (Lo and Ting, 1994; Chen andprecore mRNA levels. Our in vivo study shows therefore
specific suppression of precore mRNA synthesis directed
Hospital, 107 Messogion Ave., 11526 Athens, Greece. Fax: 30-1-
7706871. E-mail: hadziyannis@ath.forthnet.gr.
doi:10.1006/viro.2001.1352, available online at http://www.idealibrary.com
0042-6822/02 $35.00double A1762T/G1764A mutation is associated with the
HBV core promoter. © 2002 Elsevier Science (USA)
Ou, 1995), while elements in the core upstream regula-
tory sequence (CURS) (nts 1636–1742) have been shownthat the
by the
onevier Science (USA)
served.
86
to stimulate BCP activity (Yuh et al., 1992; Lo and Ting,
1994). The tissue specificity of the core promoter is
determined by several ubiquitous and liver-specific tran-
scription factors that interact with cis-acting elements
throughout the core promoter region (Lopez-Cabrera et
al., 1990; Zhang et al., 1993; Raney et al., 1997; Yu and
Mertz, 1996, 1997). In addition to sequences that regulate
transcription, this region contains elements involved in
HBV replication (Ganem and Varmus, 1987) and se-
quences essential for the trans-activating potential of the
overlapping X gene (Arii et al., 1992; Runkel et al., 1993;
Takada and Koike, 1994). These multiple functions im-
pose serious constraints on the primary structure of the
core promoter, which is highly conserved. Mutations in
this region may alter HBV gene expression, replication,
and pathogenicity.
The most frequently observed change is a double-
nucleotide mutation changing A to T at nt 1762 (A1762T)
and G to A at nt 1764 (G1764A) in the BCP (Okamoto et
al., 1994; Kurosaki et al., 1996; Kidd-Ljunggren et al.,
1997). HBV mutants carrying this double mutation have
been identified in HBeAg() patients with active liver
disease, fulminant hepatitis, and hepatocellular carci-
noma (Okamoto et al., 1994; Sato et al., 1995; Gunther et
al., 1996; Hsia et al., 1996; Kidd-Ljunggren et al., 1997;
Batista et al., 1999), but have also been reported in
asymptomatic carriers and in HBeAg() patients with
chronic hepatitis (Okamoto et al., 1994; Takahashi et al.,
1995; Laskus et al., 1995; Kurosaki et al., 1996; Lindh et
al., 1999). Although it has been proposed that this double
mutation is linked to reduced HBeAg expression by de-
creasing preC mRNA levels, it appears that its presence
has no strict correlation with disease severity, HBeAg
clearance, and the clinical course of HBV infection.
Extensive in vitro transfection studies, utilizing either
cloned HBV genomes or heterologous reporter con-
structs, have demonstrated that mutations in the core
promoter, in particular A1762T and G1764A, may alter the
balance between preC mRNA and pgRNA synthesis and
affect viral production, but have failed to agree on the
specific effects on BCP-directed gene expression and
replication efficiency (Buckwold et al., 1996; Moriyama et
al., 1996; Gunther et al., 1998). Buckwold et al. (1996)
observed a threefold decrease of preC mRNA, no
change in pgRNA levels, and enhanced encapsidation
and viral production. Moriyama et al. (1996) reported a
very strong (16- to 32-fold) reduction of preC mRNA levels
and a fourfold induction of pgRNA production leading to
enhanced replication; while Gunther et al. (1998) found a
small (0.5-fold) decrease of preC mRNA, no effect on
pgRNA levels, and a marginal, if any, increase of progeny
virus DNA. These discrepancies could be in part attrib-
uted to differences in the experimental systems but they
also point to the problems frequently associated with in
vitro transfection assays. It is unknown whether the dou-
ble A1762T/G1764A mutation decreases the levels of
preC mRNA in vivo during the natural HBV infection and
the in vivo significance of these findings remains unde-
termined. We reasoned that it is necessary to investigate
the in vivo effect of HBV core promoter mutations on the
production of precore and pregenomic transcripts in the
liver of chronically infected patients.
In this article we describe the development and appli-
cation of a sensitive and rapid transcript-specific RT-PCR
assay to investigate in vivo the effect of core promoter
mutations on the synthesis of preC mRNA and pgRNA
transcripts in the liver of patients with chronic HBV in-
fection. The entire nucleotide sequence of the HBV core
promoter/precore region was determined for each pa-
tient studied and the identified mutations were evaluated
in relation to viral RNA transcript levels.
RESULTS
Sensitivity and specificity of the transcript-specific
RT-PCR assay
A major obstacle in analyzing the synthesis of RNA
transcripts from the HBV core promoter in the liver of
infected patients has been the lack of a sensitive tech-
nique that would permit the differential detection of preC
mRNA and pgRNA transcripts in the small amount of
total RNA that can be extracted from minute biopsy
samples.
Utilizing the unique structure of the HBV genome and
transcripts, we have developed a rapid transcript-spe-
cific RT-PCR assay that allows the specific detection of
preC mRNA molecules in as little as in 330 ng of total
liver RNA and simultaneously monitors the level of total
RNA transcription (pre-C mRNA plus pgRNA) directed by
the core promoter (Fig. 1). To determine the sensitivity
and the specificity of the RT-PCR assay, in vitro synthe-
sized HBV precore (s-precRNA) and pregenomic (s-
pgRNA) RNA transcripts were serially diluted in 1 g of
total cellular RNA extracted from normal human liver and
were analyzed by the transcript-specific RT-PCR (Fig. 2).
The preC mRNA-specific 5-primer PCP was capable of
specifically detecting 103 target copies of synthetic pre-
core transcripts s-precRNA, while synthetic pregenomic
transcripts s-pgRNA were undetectable in all concentra-
tions tested (Fig. 2A). The 5-primer PGP detected both
s-precRNA and s-pgRNA transcripts with the same sen-
sitivity (Fig. 2B). Thus 103 target copies appear to be the
limit of detection of this assay transcript-specific assay.
Furthermore, a 10-fold difference in the concentration of
the synthetic RNA template resulted in a significant
change in the final PCR product, detectable for up to 105
copies of synthetic transcript, which defines the limits of
the semiquantitative range of analysis (Fig. 2). The pres-
ence of traces of contaminating DNA, despite the RQ1
DNase treatment, was monitored during the transcript-
specific RT-PCR utilizing the 5-primer M3 which hybrid-
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izes to sequences upstream from both preC mRNA and
pgRNA start sites.
The integrity of the assay was tested on DNA and RNA
samples obtained both in vitro and in vivo (Fig. 3). DNA
from plasmid pA18 containing the entire wild-type HBV
core promoter and precore sequences (nts 1593–1975)
and total cellular RNA isolated from pA18-transfected
HepG2 cells, as well as serum HBV DNA and total liver
RNA from patient 1 (Table 1), were analyzed by PCR or
the transcript-specific RT-PCR; the results are shown in
Fig. 3. Detection of cloned and serum HBV DNA se-
quences was possible with all three primers, while de-
tection of HBV RNA transcripts produced either in vitro or
in vivo was achieved only with primers PCP and PGP. No
detectable contaminating DNA was present in the RQ1-
treated RNA samples.
Detection of preC mRNA in the liver
Liver biopsy samples from 12 HBeAg() and 12
HBeAg() patients were examined for the presence of
preC mRNA. Total liver RNA (1 g) was analyzed by the
transcript-specific RT-PCR assay and the levels of de-
tected preC mRNA were compared to the total (preC
mRNA and pgRNA) RNA transcription directed by the
HBV core promoter (Fig. 4 and Table 1).
PreC mRNA was detected in the liver of all 12
HBeAg() and in 3 HBeAg() patients, while preC
mRNA was not detectable in the liver of 9 HBeAg()
patients. Specifically, high levels of preC mRNA were
found in the liver of 7 HBeAg() patients but only in 1
HBeAg() patient. Intermediate preC mRNA levels were
detected in 2 HBeAg() patients. Low but detectable
preC mRNA was found in 3 HBeAg() and 2 HBeAg()
patients (Table 1).
In contrast to the observed variability in preC mRNA,
we did not detect significant variation in the total amount
of RNA transcripts produced by the HBV core promoter in
vivo. High levels of CP-directed RNA transcripts were
found in all 24 patients regardless of HBeAg status,
serum HBV-DNA levels, and preC mRNA expression.
Total CP-directed RNA levels detected in HBeAg() pa-
FIG. 1. (A) Schematic representation and organization of the core promoter and precore/core regions of HBV. The regulatory elements that comprise
the core promoter and their corresponding nucleotide positions are shown, negative regulatory element (NRE) nts 1613–1636, core upstream
regulatory sequences (CURS) nts 1636–1742, basic core promoter (BCP) nts 1742–1849, and enhancer II (ENII) nts 1627–1774. The position of the HBV
encapsidation signal  (nts 1846–1908) is also indicated. The 5 ends of the 3.5-kb transcripts and the 3 ends of the preS/S and X gene transcripts
are shown. Primers utilized for the transcript-specific RT-PCR assay (M3, PCP, PGP, and BC1) and for sequencing (AC1 and BC1) are shown as short
horizontal arrows. Closed triangles indicate the translation initiation codons for precore and core and the open triangle the polyadenylation (Poly(A))
signal for HBV RNA transcripts. (B) Nucleotide sequence of the BCP region (nts 1742–1849). PreC mRNA and pg RNA initiation sites are marked with
vertical lines attached to horizontal arrows, indicating the origin and direction of transcription. The TATA boxes and the initiators for preC mRNA and
pg RNA are underlined. RNA initiation sites, primers, and translation start site are shown in further detail.
FIG. 2. Determination of the sensitivity and specificity of the tran-
script-specific RT-PCR assay using synthetic precore (s-precRNA) and
pregenomic (s-pgRNA) RNA transcripts. Ethidium-stained agarose gel
electrophoresis of RT-PCR products. (A) PreC RNA detection using 5
primer PCP. (B) Total CP-directed RNA detection using 5 primer PGP.
The number of synthetic RNA target copies was calculated based on
optical density readings.
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tients were equivalent and in some cases higher than
those observed in HBeAg() patients with high levels of
preC mRNA. The difference in the levels of total CP-
directed RNA to preC mRNA transcripts produced by
wild-type isolates (patients 1 and 9) was determined to
be less than 10-fold by endpoint dilution PCR (data not
shown).
Sequence analysis of the core promoter and precore
region
The complete nucleotide sequence of the core pro-
moter and the precore region (nts 1613–1955) was ana-
lyzed for each of the 24 patients and the results were
compared to genotype D, ayw subtype, reference se-
quence (Galibert et al., 1979) (Fig. 5).
The majority of core promoter and precore sequences
was found to be highly conserved. The apparent variabil-
ity by comparison to the reference sequence, observed
at nucleotide positions 1635/1637 and 1676/1678, is gen-
otype-related variation characteristic of the of the HBV
genotype D strain which is endemic to Greece (unpub-
lished observations). HBV isolates from patients 6 and 7
(Fig. 5) belong to genotype A and differ in these and other
positions from the rest of the isolates that belong to
genotype D. Two highly variable areas were identified,
one in the BCP between nucleotides 1752 and 1773 and
one at nucleotide positions 1896 and 1899 in the coding
precore region (Fig. 5).
The double A1762T/G1764A mutation in the BCP was
found in 11 of 24 patients, 3 HBeAg() and 8 HBeAg(),
while a single G3 T mutation at nt 1764 was detected in
2 HBeAg() patients. Additional mutations in the BCP
between nts 1760 and 1768 were detected in 1 HBeAg()
and 4 HBeAg() and point mutations at nt 1753 in 5
HBeAg() and 10 HBeAg() patients. One HBeAg()
and 3 HBeAg() patients harbored a C3 A mutation at
nt 1653 in the CURS region (Fig. 5 and Table 1).
Mutations in the precore region preventing HBeAg
expression were found in 13 of 24 patients. Eleven of 12
HBeAg() patients had the G 3 A change at nt 1896,
introducing a translational stop at codon 28 and 2 of 12
HBeAg() patients had a G and A mixture in this posi-
tion. In addition to G1896A, 2 HBeAg() patients had a
C3 T mutation at nt 1817 in the second precore codon,
introducing another stop codon immediately after the
initiation codon to the precore region. Furthermore, 8 of
the 11 HBeAg() patients with G1896A also harbored the
double A1762T/G1764A BCP mutation.
Effect of core promoter mutations on preC mRNA
levels
To evaluate the effect of the detected core promoter
and precore mutations on the transcriptional activity of
the core promoter, we compared the results of the se-
quence analysis with the preC and total CP-directed viral
transcript levels for each patient (Table 1). The presence
of the double A1762T/G1764A mutation in 11 cases was
always associated either with a dramatic reduction or
with a complete abolition of preC mRNA levels in the
liver of infected patients without significantly affecting
the levels of total CP-directed transcription.
Precore mRNA synthesis was selectively suppressed
by the A1762T/G1764A mutation regardless of the pres-
ence of precore stop codon mutation G1896A. In fact, the
BCP double mutation was predominantly found in
HBeAg() patients and usually in association with
G1896A. Seven of eight HBeAg() patients harboring the
A1762T/G1764A mutation also had the precore mutation
G1896A. All of these patients had undetectable or very
low preC mRNA levels. Three HBeAg() patients with
undetectable levels of preC mRNA and high levels of
total CP-directed transcripts had single-point mutations
at either position of the 1762/1764 nucleotide pair to-
gether with additional mutations in close proximity (nts
1758–1768) that fall within the transcription factor binding
region (Table 1). One HBeAg() patient with wild-type
sequence at nt 1896 harboring the double A1762T/
G1764A mutation had undetectable preC mRNA levels
FIG. 3. In vitro and in vivo detection of HBV core promoter/precore region DNA and core promoter-directed RNA transcripts by PCR and RT-PCR
assays. Agarose gel electrophoresis of PCR/RT-PCR products. In vitro: wild-type core promoter/precore sequences from patient 1 were cloned and
the recombinant plasmid (pA18) was used to transfect HepG2 human hepatoblastoma cells. Recombinant plasmid DNA and total RNA from the
pA18-transfected HepG2 cells were analyzed by PCR and RT-PCR, respectively. In vivo: serum HBV DNA and total liver RNA extracted from a liver
biopsy sample of patient 1 were analyzed by PCR and RT-PCR, respectively.
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(patient 17, Table 1). The observed suppression of preC
mRNA production is the most likely mechanism for ex-
plaining the HBeAg() status of this patient.
In contrast, one HBeAg() patient with G1896A but
without the double BCP mutation and nine HBeAg()
patients with wild-type sequence at nts 1762 and 1764
had high levels of both preC mRNA and total CP-directed
transcription. Overall, 11 of 12 HbeAg-negative and 4 of
12 HbeAg-positive patients with BCP mutations had re-
duced preC mRNA levels.
Other mutations in the core promoter were found in 4
HBeAg() and 11 HBeAg() patients with reduced
TABLE 1
Mutations in the HBV Core Promoter/Precore Region and In Vivo Levels of Core Promoter-Directed RNA Transcripts
Patient No. HBeAg
Nucleotide mutations
RNA expressionbPrecore Basic core promoter
nt1896 nt1762 nt1764 Other proximala Precore Total
1 () wt wt wt () ()
2 () wt wt wt () ()
3 () wt wt wt 61C () ()
4 () G/A wt wt () ()
5 () G/A wt wt () ()
6 () wt wt wt () ()
7 () wt wt wt () ()
8 () wt T A () ()
9 () wt wt wt () ()
10 () wt T A () ()
11 () wt T A () ()
12 () wt wt wt () ()
13 () A T A () ()
14 () A wt T 61C, 63T, 66G () ()
15 () A T A () ()
16 () A T A () ()
17 () wt T A () ()
18 () A wt wt () ()
19 () A T A 66T, 68A () ()
20 () A T A () ()
21 () A wt T 66G () ()
22 () A T A () ()
23 () A T wt 58A, 66A, 67C () ()
24 () A T A () ()
a Mutations in the putative transcription factor binding region between nts 1758 and 1768.
b Precore mRNA and total RNA levels produced by the CP for each patient were compared to wild-type transcript levels and evaluated in a
semiquantitative fashion as high (), intermediate (), low (), or undetectable ().
FIG. 4. In vivo detection of precore mRNA levels by transcript-specific RT-PCR. Total liver RNA extracted from liver biopsy samples was analyzed by
transcript-specific RT-PCR for the detection of preC-mRNA (5 primer PCP), total core promoter-directed transcription (5 primer PGP), and for the presence
of contaminating HBV DNA (5 primer M3). Gel electrophoresis of the RT-PCR products from 2 HBeAg() (patients 3 and 9) and 2 HBeAg() (patients 16
and 22) patients. For each patient HBeAg status and core promoter/precore mutations are indicated for nt positions 1653, 1758, 1762, 1764, and 1896.
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mRNA synthesis. The C 3 T mutation at nt 1653 in the
CURS region was detected in four patients with BCP
mutations and reduced preC mRNA levels. Mutations at
nt 1753 (most frequently T 3 C) were associated both
with the presence of the A1762T/G1764A mutation and
with decreased preC mRNA production. However, the
existence of the 1753C mutation alone, one HBeAg()
and one HBeAg() patient, did not significantly affect
preC mRNA levels in the liver.
DISCUSSION
Mutations in the HBV core promoter have been the
focus of intense investigation in recent years. A number
of studies have shown that the most frequently encoun-
tered double A1762T/G1764A BCP mutation is widely
prevalent among both HBeAg() and HBeAg() patients
and have suggested an association of this and other
BCP mutants with disease activity (Sato et al., 1995;
Baumert et al., 1996; Gunther et al., 1996; Sterneck et al.,
1996; MacMillan et al., 1996; Pult et al., 1997). Originally
it was proposed that this double mutation is selected to
downregulate HBeAg production in genotype A viral
strains that cannot develop the G1896A mutation due to
structural constrains of the encapsidation signal (Chan
et al., 1999). However, the functional significance of this
mutation, as well as the reasons for the frequent selec-
tion of these viral variants, remain unresolved. In vitro
investigations have produced discordant results con-
cerning the effect of the A1762T/G1764A mutation on
preC mRNA and pgRNA production and viral replication,
but there has been no in vivo data to evaluate the in vitro
findings.
In vivo differential detection of preC mRNA and pgRNA
transcripts is not possible by traditional techniques such
as primer extension or S1 nuclease protection, since
large amounts of total liver RNA (10–30 g) are required
for these assays (Yuh et al., 1992; Gunther et al., 1998).
Transcript-specific detection is further complicated by
the overlapping nature of the HBV transcription units
(Ganem and Varmus, 1987). To investigate in vivo the
effect of core promoter mutations on the synthesis of
preC mRNA and pgRNA transcripts, we have developed
the described sensitive and rapid transcript-specific RT-
PCR assay that allows the specific detection of preC-
mRNA transcripts in the liver of infected patients.
In designing the transcript-specific RT-PCR assay we
have positioned the 3 primer downstream from the poly-
adenylation site, which is common for all HBV tran-
scripts. The unique sequences present at the 5 end of
the 3.5-kb RNAs allow distinction between them and the
rest of the HBV transcripts (Fig. 1). Specific detection of
the longer precore transcript is accomplished by posi-
tioning the 5 primer in the small region between the
preC mRNA and the pgRNA start sites. A second 5
primer positioned downstream from both start sites mon-
itors the total CP-directed transcription, which serves as
the internal control for the integrity of the assay. This
method allows the specific detection of preC-RNA tran-
scripts in the liver of HBV-infected patients but it can also
be utilized in parallel in vitro studies.
The results of our in vivo study show that the double
A1762T/G1764A mutation in the HBV core promoter is
associated with the specific and preferential suppres-
sion of precore mRNA synthesis in the liver of infected
patients without significantly affecting the levels of total
HBV core promoter-directed transcription. These data
provide the first in vivo support to those in vitro obser-
vations, indicating that the double A1762T/G1764A muta-
tion suppresses preC mRNA transcription efficiency
(Buckwold et al., 1996; Moriyama et al., 1996) and that the
synthesis of preC mRNA and pgRNA is differentially
regulated by cis-acting sequences in the core promoter
and trans-acting viral and cellular factors (Chen et al.,
1995; Yu and Mertz, 1996, 1997; Li et al., 1999). Previous
in vitro studies have reported reduction of preC mRNA
levels in 1762T/1764 variants ranging from [0.5]- to 32-
fold decrease (Buckwold et al., 1996; Moriyama et al.,
1996; Gunther et al., 1998). Our in vivo data, showing
suppression of preC mRNA levels ranging from signifi-
cant reduction to complete abolition in the presence of
the A1762T/G1764A mutations, are in agreement with
these observations. The reasons for the observed vari-
ability in preC mRNA levels are not clear but it appears
that other CP and adjacent BCP mutations may have a
significant influence on preC mRNA production.
The precise molecular mechanism underlying the ob-
served changes in preC mRNA levels is not well under-
stood. Since reduced levels of preC mRNA were most
commonly observed in G1896A mutant strains, in which
translation of the preC mRNA is prematurely terminated,
it could be argued that the detected changes in steady-
state preC RNA levels do not reflect decreased mRNA
synthesis due to mutations in the CP but rather in-
creased instability of the untranslated preC transcripts.
This is not likely to be the case, however, since one
HBeAg() patient lacking the double BCP mutation with
G1896A had high levels of preC mRNA (patient 18, Table
1) and conversely, one HBeAg() (patient 17, Table 1)
and three HBeAg() patients with wild-type precore se-
quences harboring the A1762T/G1764A BCP mutation
had undetectable or significantly reduced preC mRNA
levels.
The accumulation of the selected CP mutations in
regions involved in the binding of ubiquitous and liver-
specific transcription factors suggests that, at least to
some extent, these mutations exert their effect by mod-
ulating transcription from the CP promoter. Patients har-
boring the double A1762T/G1764A mutation, as well as
patients with single nucleotide mutations at either 1762
or 1764 and additional BCP mutations between nts 1758
and 1768 (patients 14, 21, and 23, Table 1) have reduced
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or undetectable preC mRNA levels. This region overlaps
with the binding sites of several transcription factors,
including Sp1, HNF4, LEF (COUP-TF), C/EBP, and TBP,
that regulate transcription from the core promoter (Zhang
et al., 1993; Raney et al., 1997; Yu and Mertz, 1996, 1997).
The C1653T which alters a C/EBP binding site in the
CURS region (Lopez-Cabrera et al., 1990) was found in
four patients with reduced preC mRNA levels. Mutations
in these regions have been shown to alter the binding of
protein factors and/or influence CP-directed transcription
(Zhang and McLachlan, 1994; Buckwold et al., 1996;
Gunther et al., 1996, 1998; Moriyama et al., 1996; Pult et
al., 1997; Yu and Mertz, 1996, 1997; Li et al., 1999). We
consider this to be the most likely mechanism for the in
vivo repression of preC mRNA levels.
An interesting finding is that although in this study the
A1762T/G1764A mutation was always associated with
impaired preC mRNA synthesis it was not strictly asso-
ciated with the HBeAg() phenotype. In fact, the A1762T/
G1764A mutation is highly prevalent both in HBeAg()
and in HBeAg() patients with active liver disease (Oka-
moto et al., 1994; Laskus et al., 1995; Takahashi et al.,
1995; Kurosaki et al., 1996; Lindh et al.,1999). Further-
more, we found that this double mutation is frequently
present in HBeAg() precore mutant strains concomi-
tantly with G1896A, implying that the two mutations are
not functionally equivalent. Therefore reduction of
HBeAg levels might not be the major mechanism for the
emergence of this mutant as has been previously sug-
gested for genotype A HBV genomes (Chan et al., 1999).
It appears that these promoter mutants are further se-
lected to downregulate preC mRNA synthesis rather than
HBeAg expression, suggesting that in addition to remov-
ing an immunomodulatory protein they may also confer a
replicative advantage to the virus.
One possibility is that by suppressing the levels of
preC mRNA production, the A1762T/G1764A mutation
may induce increased pgRNA production. Transcription
from two proximal start points may be subject to pro-
moter occlusion. In fact, it has been shown that the preC
and other upstream HBV transcripts competitively inhibit
the formation of the transcriptional complex at the
pgRNA start point (Schaller and Fischer, 1991).
In our in vivo study, despite the dramatic reduction of
preC mRNA synthesis observed in A1762T/G1764A mu-
tants, the levels of total CP-directed transcription were
not significantly affected, suggesting an increase in
pgRNA synthesis. However, the transcript-specific RT-
PCR assay utilized in this study is a semiquantitative
assay and small variations of pgRNA levels observed by
other investigators cannot be assessed herein. There-
fore, although our in vivo analysis has unequivocally
documented the downregulation of preC mRNA by mu-
tations in the core promoter, further studies are required
to quantify these changes and to elucidate the in vivo
effect of these mutations on pgRNA production and viral
replication.
Several in vitro experiments have shown that core
promoter mutations in addition to modulating CP-di-
rected transcription may also enhance viral encapsida-
tion and replication (Buckwold et al., 1996; Moriyama et
al., 1996). It has been proposed that these mutations may
directly act to induce a translational or posttranslational
effect in core protein production, resulting in enhanced
viral encapsidation and replication independent of preC
mRNA and pgRNA transcript levels (Baumert et al., 1996,
1998). Delineation of the precise molecular mechanism
that governs HBV replication requires further in vitro
studies in tissue culture systems as well as in vivo
functional analysis of HBV mutants.
In conclusion, this study provides the first in vivo evi-
dence that the double A1762T/G1764A mutation in the
HBV core promoter is associated with specific and pref-
erential suppression of precore mRNA synthesis during
natural HBV infection. The regulation of precore and
pregenomic RNA synthesis appears to be a pivotal step
in the life cycle of HBV and the elucidation of the factors
involved may contribute to a better understanding of HBV
replication and its relevance in the pathogenesis of liver
disease.
MATERIALS AND METHODS
Patients and biological samples
We studied 24 patients with chronic hepatitis B: 12
HBeAg(), 10 males and 2 females, mean age 38.3 
12.4 years old; and 12 HBeAg(), 9 males and 3 females,
mean age 43.2  13.5 years old. All patients had active
liver disease—nine had established cirrhosis (four
HBeAg positive, five HBeAg negative)—with persistent
biochemical activity (serum ALT levels  two times the
upper limit of normal value) and had been on long-term
follow up on an outpatient basis. The degree of hepatic
inflammation and fibrosis was assessed according to
Ishak et al. (1995). All patients were negative for sero-
logical markers for hepatitis D (HDV), hepatitis C (HCV),
and HIV infection. None consumed alcohol or were tak-
ing immunosuppressive drugs. Serological markers of
HBV infection, namely HBsAg, HBeAg, and anti-Hbe,
were tested by radioimmunoassay (RIA; Sorin Biomedica
S.p.A, Saluccia, Italy). Serum HBV DNA levels were de-
termined by a commercially available quantitative PCR
assay (Amplicor HBV Monitor Test, Roche Diagnostics,
Mannheim, Germany). Liver biopsies and serum sam-
ples collected at the time of liver biopsy were stored at
70°C until analysis.
Transcript-specific RT-PCR
Total liver RNA was extracted from liver biopsy sam-
ples using a modified guanidinium thiocyanate-phenol
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procedure (TriPure; Boehringer Mannheim, Mannheim,
Germany) according to manufacturers’ instructions. RNA
samples were subsequently treated with RQ1 RNase-
free DNase (Promega, Madison, WI) at a concentration of
1 u/g of nucleic acid for 1 h at 37°C, to remove con-
taminating DNA. One microgram of total liver RNA, as
determined by spectrophotometry, was used for cDNA
synthesis with antisense primer BC1 (5-GGAAAGAAGT-
CAGAAGGCAA, nt 1974–1955) and Moloney murine leu-
kemia virus (M-MLV) reverse transcriptase (RT). The ex-
tracted liver RNA (1 g) was incubated for 40 min at 42°C
in 60 ml of reaction mixture containing 50 pmol cDNA
primer, 50 mM Tris (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10
mM dithiothreitol, 1 mM dTNTp, 20 u Rnase inhibitor
Rnasin (Promega), and 300 u M-MLV RT (Promega).
Twenty microliters of the cDNA product was used in
each of three separate amplification reactions with BC1
as the common 3 primer and 5 primers: (1) PCP (5-
GGTCTGCGCACCAGCACC nts 1796–1813) for the spe-
cific detection of preC mRNA transcripts; (2) PGP (5-
CACCTCTGCCTAATCATC nts 1826–1843) for monitoring
total CP-directed transcription; and (3) M3 (5-CTGG-
GAGGAGTTGGGGGAGGAGATT nts 1730–1754) for de-
tecting contaminating HBV DNA molecules (Fig. 1). All
primer sequences were selected from highly conserved
HBV regions. Viral sequences were amplified with 30
pmol of each primer, using Taq DNA polymerase (Boeh-
ringer Mannheim) for 40 cycles (94°C 1 min, 50°C 1.5
min, 72°C 1 min) under standard PCR conditions. Pre-
cautions were taken to prevent cross-contamination of
PCR samples. Fifteen microliters of the amplification
product was analyzed by agarose gel electrophoresis.
Detection of PreC mRNA produces a 178-bp fragment,
total CP directed transcription produces a 148-bp prod-
uct, and contaminating DNA molecules produces a
244-bp fragment—primer-dimers and higher molecular
weight nonspecific products typical of RT-PCR assays
were infrequently observed in some lanes. Precore
mRNA and total RNA levels produced by the core pro-
moter for each patient were compared to wild-type tran-
script levels, produced both in vitro and in vivo, and
evaluated in a semiquantitative fashion as high, interme-
diate, low, or undetectable.
The sensitivity and specificity of the strand-specific
RT-PCR assay was determined by serial 10-fold dilutions
of synthetic RNA transcripts in 1 g of total cellular RNA
extracted from normal human liver. Synthetic precore
(s-precRNA) and pregenomic (s-pgRNA) transcripts en-
compassing HBV genome nt positions 1796–1975 and
1826–1975, respectively, were synthesized from linear-
ized plasmid clones using Riboprobe Combination Sys-
tems (Promega). The DNA template was removed by
digestion with RQ1 RNase-free DNase as before. Tran-
scription products were run on agarose gel to ensure the
quality of the synthetic transcripts and the RNA was
quantitated by optical density readings. The effective
removal of residual plasmid DNA was monitored by run-
ning PCR controls where the reverse transcription step
was omitted.
DNA extraction, PCR amplification, and sequencing
HBV DNA was extracted from 220 l of serum which
was digested with 0.6 u proteinase K (Promega) in 10
mM Tris–hydrochloride, 5 mM EDTA, and 5% sodium
dodecyl sulfate at 56°C for 2 h. After phenol/chloroform
extraction and ethanol precipitation, the nucleic acid
pellet was resuspended in 100 l water and 10 l ali-
quots were used for each PCR assay. For direct sequenc-
ing serum HBV DNA was amplified with 30 pmol each of
primers X1A (5-TTGCTCGCAGCAGGTCTGGAG, nt 1295–
1315) and 1AC (5-CACCCACCCAGGTAGCTAGAG nt
2120–2100) for 40 cycles (95°C 1 min, 50°C 1 min, 72°C
1.5 min). When necessary, 5 l of the first PCR product
was amplified in a nested PCR with 30 pmol each of each
internal primer AC1 (5-CACCTCTGCACGTCGCATGG, nt
1592–1611) and BC1 (5-GGAAAGAAGTCAGAAGGCAA,
nt 1974–1955), using Taq DNA polymerase (Boehringer
Mannheim) for 40 cycles (94°C 1 min, 44°C 1.5 min, 72°C
1 min) under standard PCR conditions. Appropriate mea-
sures were taken to prevent contamination. In the case
of DNA extracted from liver samples, 1 g of total liver
DNA was used for each amplification reaction as de-
scribed above.
The PCR products were gel purified (QIAquick Gel
Extraction Kit, Qiagen, Hilden, Germany) and both anti-
sense and sense strands were sequenced with Cy5.5/
Cy5-labeled sequencing primers AC1 and BC1, respec-
tively, using the Cy5/Cy5.5 Dye Primer Cycle Sequencing
Kit and the Open Gene automated DNA sequencing
system (Visible Genetics Inc., Toronto, ON, Canada), ac-
cording to the manufacturer’s instructions.
HBV genotyping
HBV S gene and polymerase sequences were deter-
mined as described previously (Hadziyannis et al., 2000)
using amplification primers S1 (5-ATGGAGAACATCA-
CATCAGGA, nt 157–177) and POL3 (5-AAGGATCCAGT-
TGGC nt 1409–1395) for 40 cycles (95°C 1 min, 48°C 1
min, 72°C 1.5 min) and Cy5/Cy5.5-labeled sequencing
primers S3 (5-CAAGGTATGTTGCCCGTTTG, nt 455–474)
and S1R (5-TTAGGGTTTAAATGTATACCC, nt 842–822).
HBV genotypes were determined by comparing the ob-
tained S gene (nt 477–821) and CP/precore (nt 1612–
1954) nucleotide sequence with published sequences
(Norder et al., 1994).
Clones and transfections
Human hepatoma HepG2 cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM; Gibco BRL,
Life Technologies, Ltd., Paisley, Scotland) supplemented
with 10% fetal bovine serum (Gibco BRL) at 37°C in a 5%
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CO2 atmosphere. Cells were transfected using an acti-
vated-dendrimer method (SuperFect Transfection Re-
agent, Qiagen) with plasmid pA18 containing wild-type
HBV core promoter and precore sequences (nts 1593–
1975) cloned in to the EcoRV site of pBCSK() phagemid
(Stratagene, La Jolla, CA). Total cellular RNA and DNA
were extracted from transfected cells using a modified
guanidinium thiocyanate-phenol procedure (TriPure;
Boehringer) and quantitated by spectrophotometric anal-
ysis. Differences in transfection efficiency were moni-
tored and normalized by cotransfection with the pSV--
Galactosidase Control Vector (Promega).
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